Markets

Clovis Oncology, Inc. (CLVS) in Focus: Stock Surges 16 % - Tale of the Tape

Clovis Oncology, Inc. ( CLVS ) was a big mover last session as the company saw its shares surge 16% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. This broke the recent trend of the company, as the stock is now trading above the volatile price range of $47.83 to $54.91 in the past one-month time frame.

The company has seen 2 downward revisions in the past month, while its Zacks Consensus Estimate of a loss widened over the same timeframe, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Clovis Oncology currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Other attractive players in the healthcare industry include Gilead Sciences Inc. ( GILD ), Myriad Genetics Inc. ( MYGN ) and ANI Pharmaceuticals, Inc. ( ANIP ), all carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

MYRIAD GENETICS (MYGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MYGN GILD ANIP CLVS

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More